ArticleNeurology(R) neuroimmunology & neuroinflammation2017
An observational study of alemtuzumab following fingolimod for multiple sclerosis.
Mark Willis et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this papertrialcites it